The University of South Florida, also known as USF, is a member institution of the State University System of Florida, one of the state's three flagship universities for public research, and is located in Tampa, Florida, USA. Founded in 1956, USF is the eighth largest university in the nation and the third largest in the state of Florida, with a total enrollment of 47,122 as of 2009. USF has an autonomous campus in St. Petersburg, and branch centers in Sarasota and Lakeland. Wikipedia.
H. Lee Moffitt Cancer Center, Research Institute and University of South Florida | Date: 2017-05-03
The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.
University of South Florida and Transgenex Therapeutics LLC | Date: 2017-03-29
Described herein are compositions and methods of forming multi-cellular tumoroids. Also described herein are methods of using the multi-cellular tumoroids.
University of South Florida, King Abdullah University of Science and Technology | Date: 2017-02-08
Embodiments of the present disclosure provide for metal-organic materials (MOMs), systems that exhibit permanent porosity and using hydrophobic MOMs to separate components in a gas, methods of separating CO_(2 )from a gas, and the like.
University of South Florida | Date: 2017-03-07
The ketogenic diet (KD) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mM) without need for dietary restriction. The effects of ketogenic agents were tested on blood glucose, ketones, and lipids with a 28-day dose escalation study in male Sprague-Dawley rats: R,S-1,3-Butandiol (BD), acetoacetate ketone ester (KE), and control (H_(2)O) (n8). Days 1-28, rats received a daily 5 g/kg intragastric gavage, based on previous toxicology studies. Once weekly, whole blood samples (10 l) were acquired for analysis of glucose and HB at 0, 0.5, 1, 4, 8, and 12 hours after test substance administration, or until HB returned to baseline. At day 1 and 28, 10 L of whole blood were collected to measure triglycerides, total cholesterol, and HDL concentration. Significant elevation of blood ketone was observed with a significant inverse relationship with blood glucose for the duration of the experiment. There were no significant changes in the lipid panel for any of the substances. There were significant reductions in body weight when animals were treated with either BD or KE as compared to control.
University of South Florida | Date: 2017-02-27
The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while stimulating angiogenesis. The subject invention also concerns methods for preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor.
University of South Florida | Date: 2017-03-06
System and methodology objectively capture clinical data on oral health and provide standardized scoring for quantifying oral health. The process of capturing clinical data is based on use of an intraoral camera with imaging software that has the capacity to capture digital images of all tooth surfaces. Digital plaque data are collected in a standardized manner per tooth, and with the ability to select optimal frames for analysis. Data are extracted per tooth into a software program. Color classification of each pixel is determined by the software program using an algorithm that makes use of red/green/blue color code combinations. These classifications are then quantitatively used within the software program and separate algorithms that automatically generate a range of oral health scoring techniques.
University of South Florida | Date: 2017-03-13
A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourettes Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depressoin, an anxiety disorder, schizophrenia, a seizure disorder, Parkinsons disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohns disease, autonomic dysreflexia, and spasmogenic intestinal disorders.
University of South Florida | Date: 2017-02-06
The invention relates to a pharmaceutical composition comprising an ionic co-crystal (ICC) of lithium with salicylic acid and 1-proline (LISPRO). The pharmaceutical composition can further comprise an anti-inflammatory agent, for example, salicylic acid. An embodiment of the invention provides a method for treating Fragile X Syndrome (FXS) in a subject by administering to the subject a composition comprising a pharmaceutically effective amount of LISPRO.
University of South Florida | Date: 2017-04-14
This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
University of South Florida | Date: 2017-04-18
Provided herein is a three-dimensional scaffold composition comprising randomly oriented fibers, wherein the fibers comprise a polyethylene glycol-polylactic acid block copolymer (PEG-PLA) and a poly(lactic-co-glycolic acid) (PLGA). Also provided are methods for using the three-dimensional scaffolds described herein.